CYP2C9 — Cytochrome P450 2C9
Chromosome 10q23.33
Metabolizes ~15% of clinical drugs including warfarin (S-enantiomer), NSAIDs, sulfonylureas, and losartan. CYP2C9 genotype is part of FDA warfarin dosing guidelines.
Pharmacogenomic Variants
Peptide Therapeutic Approaches
Genotype-independent anticoagulant peptides that bypass CYP2C9 metabolism entirely, targeting thrombin or Factor Xa directly.
Related Therapeutics
Associated Conditions
Genetic variation in VKORC1 and CYP2C9 determines warfarin dose requirements. FDA recommends pharmacogenomic testing, and genotype-guided dosing reduces bleeding events by 30%. It is the most established pharmacogenomic application in clinical practice.
Drug Metabolism Disorders (CYP450 Pharmacogenomics)Genetic variation in cytochrome P450 enzymes (CYP2D6, CYP2C19, CYP2C9) creates a spectrum from ultra-rapid to poor metabolizers. This affects ~25% of all prescribed medications and is the foundation of clinical pharmacogenomics.
Analyze CYP2C9 variants with PepFold
Submit rs1799853, rs1057910 and get ranked peptide candidates in under 2 minutes.